Mesoblast Sold $115M of Ryoncil in Year One. The Cash-Flow Crossover Is Next

Mesoblast reported its first full fiscal year of an approved drug's revenue on Wednesday: Ryoncil net revenue of US$36 million in the fourth quarter, US$115 million for the year, a record quarter on top of a compounding launch. The stock fell about 2% in regular trading anyway. A commercial-scale result drawing a biotech-scale reaction is the most useful fact in the release, because it shows the market is no longer waiting for proof that Ryoncil sells. It is waiting for proof that the revenue turns into cash.

The skepticism is earned, and it goes back years. This was the company the FDA rejected twice for this exact product — a complete response letter in October 2020, then another in August 2023 asking for more data — while it lived on dilution and expensive debt, including a 15% subordinated loan sitting under the senior creditor, Oaktree. The turn came on December 18, 2024, when the agency approved Ryoncil, the first mesenchymal stromal cell therapy cleared in the United States, for steroid-refractory acute graft-versus-host disease in children; commercial sales began March 28, 2025. The stock's 52-week range of $12.66 to $21.50 is that history in miniature: a beaten-down biotech re-rated into a mid-price question mark.

Now look at the numbers that don't require faith. Ryoncil net revenue ran roughly $19 million, $30 million, $30 million and $36 million across the four quarters of fiscal 2026 — about $48.7 million in the first half, $66.5 million in the second. Around nine of every ten dollars reached gross profit, and the full-year net loss narrowed 44%, to $57.5 million. The line this whole case rests on is the company's own disclosure of net operating cash spend: $50 million in fiscal 2025, $43.8 million in fiscal 2026, and just $13.4 million in the second half, with the March quarter down to $4.1 million. Launch costs have stopped being the story.

The balance sheet was rebuilt to match. In December 2025 Mesoblast retired the Oaktree facility and paid down the NovaQuest royalty debt, replacing them with a five-year, 8% credit line from director and shareholder Dr. Gregory George, secured only by a Temcell royalty stream. By June 30 the full $125 million was drawn, leaving $103 million of cash against roughly $22 million of net debt on a market value near $2.2 billion. The distress-era financing that forced dilution is gone; the cost of carrying the debt is down; nothing material is pledged.

Here is the honest gap, stated plainly: free cash flow is not yet positive, and management's guidance was carefully worded on the call. It pointed to profitability in the 2027 fiscal year, a lower cash burn than 2026 and double-digit Ryoncil growth over the next twelve months — but when the CFO was asked to date cash-flow positivity from operations, he declined, citing quarter-to-quarter swings in R&D and manufacturing. Free cash flow is the anchor a case like this usually rests on, and it has not arrived. That is the higher-uncertainty part, and it deserves to be named.

Do the arithmetic and you can see why breakeven is plausible rather than guaranteed. The fourth quarter's $36 million annualizes to roughly $144 million. At a ~90% gross margin that is on the order of $130 million of gross profit, against an operating cost base plus roughly $10 million of annual interest that fiscal 2026's cash-spend history suggests can be held near $55 million. Mid-teens revenue growth in fiscal 2027 puts the top line comfortably over the cost line — and working capital is the swinging factor the CFO refuses to schedule, which is exactly what inventory builds, receivables timing and trial manufacturing would do. Fair. So the proof point is quarterly: watch net operating cash spend and Ryoncil's quarterly revenue in the same report.

The part that should hold your attention is what the price already assumes. Against Ryoncil's $115 million, today's ~$2.2 billion market value is roughly 19 times trailing revenue, or about 15 times the fourth-quarter run rate. That is not a beaten-down price; it is a commercial-launch price that presumes the pipeline arrives. The aggregate signal from AInvest still labels the stock Buy, and the street's price targets sit near $35, above the tape — meaning the aggregate stance already reflects the re-rating story, not lingering doubt. The market's impatience on a quarter that merely matched estimates is the tell: expectations have shifted from "will there ever be revenue?" to "deliver it every quarter," while the operating setup keeps getting cleaner underneath.

Stick that impatience onto the real risks and you get the break conditions. This is one product in one narrow indication: pediatric steroid-refractory GVHD, a small, well-defined population. The adult expansion trial — 180 patients across more than 40 U.S. sites with the BMT-CTN network, an addressable adult SR-aGVHD pool that covers a big share of the roughly 8,500 allogeneic transplants performed in the U.S. each year — has an interim analysis planned for the fourth quarter of 2027, vetted with the FDA so that either the interim or the full result could support an expanded label. The larger prize, chronic low back pain, finished treatment enrollment at more than 300 patients and reads out in the second half of 2027 — the same program that had to be rebuilt around a new 12-month pain endpoint after the first large trial drew FDA feedback, so history says it can disappoint. If Ryoncil revenue goes flat for two consecutive quarters, or the cash-spend line stops falling while sales keep growing, or either readout fails, a low-teens forward sales multiple with no free cash flow underneath it gets repriced quickly.

I can be wrong again — the CFO's refusal to date the crossover is the honest tell that quarterly timing is genuinely lumpy. But the specifics are what make this one worth tracking: a company whose net operating cash spend was $4.1 million three months ago, sitting on $103 million of cash, whose remaining market risk is execution rather than survival. When the quarterly cash-spend line crosses zero while Ryoncil still grows, the old story closes for good. Until then the case is one number, updated every quarter.